化学发光免疫分析在肿瘤标志物检测中的应用

郭玉华; 屈凌波; 吴拥军; 薛乐勋

郭玉华 , 屈凌波 , 吴拥军 , 薛乐勋

文章导航 > 国际放射医学核医学杂志 > 2004, 28 > 5: (220-221,229)

引用本文:

Citation:

化学发光免疫分析在肿瘤标志物检测中的应用

1. 450052 郑州, 郑州大学化学系;
2. 455002 安阳, 安阳师范学院;
3. 450052 郑州, 郑州大学分子医学重点实验室
基金项目:
郑州大学"211工程"重点学科研究项目"肿瘤与生物工程"课题
中图分类号: R446.6

The application of chemiluminescent immunoassay in evaluation of tumor markers

1. Department of Chemistry, Zhengzhou University, Zhengzhou 450052, China;
2. Anyang Normal College, Anyang 455002, China;
3. Key Laboratory of Molecular Medicine, Zhengzhou University, Zhengzhou 450052, China
CLC number: R446.6

摘要: 简要介绍了肿瘤标志物的一般概念及化学发光免疫分析的原理,综述了近年来化学发光免疫分析在主要的肿瘤标志物检测中的应用进展,并对化学发光免疫分析研究肿瘤标志物今后的发展提出展望。
- 化学发光免疫分析 /
- 肿瘤标志物
Abstract: The theory of tumor markers and chemiluminescent immunoassay was introduced briefly. The recent application of chemiluminescent immunoassay in evaluation of tumor markers was reviewed, and the development of its application in evaluation of tumor markers in future was also viewed.
- chemiluminescent immunoassay /
- tumor markers
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Yan G,Ju H,Liang Z,et al.Technical and clinical comparison of two fully automated methods for the immunoassay of CA125 in serum[J].J Immunol Methods,1999,225(1-2):1-8.
[2]	Candido DRFJ,Moreirade AJ,Bighetti S.CA125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors[J].Gynecol Obstet Invest,2002,54(3):132-136.
[3]	Fujiwara H,Kinugasa H,Inaoka Y.Basic and clinical evaluation of the automatic chemiluminescent immunoassay apparatus ARCHITECT CA199[J].Igaku Yakugaku,1999,41(5):1031-1041.
[4]	王文耀,胡先贵,曹贵松,等.胰腺癌患者外周血桨中K-ras基因突变和CA199联合检测的临床意义[J].解放军医学杂志,2002,27(5):455-456.
[5]	Arai K,Umeda H,Horimi H,et al.Fundamental and clinical evaluation of prostatic acid phosphatase measurement by CLIA[J].Igaku to Yakugaku,1998,39(5):1011-1018.
[6]	Oed M,Ametmann R,Lower Y,et al.LIAISON hCG:an automated chemiluminescent immunoassay for the determination of human chorionic gonadotropin[J].Anticancer Res,1999,19(4A):2735-2737.
[7]	Adachi T,Moriya K,Esaki K.Clinical evaluation of chemilumi-nescent immunoassay PSA for detection of prostate cancer[J].Hinyokika Kiyo,1998,44(7):469-476.
[8]	Wesseling S,Stephan C,Semjonow A,et al.Determination of non-alpha-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen:analytical performance and diagnostic accuracy[J].Clin Chem,2003,49(6Pt1):887-894.
[9]	Sanchez C,Espasa A,Chinchilla V,et al.New electrochemilumi-nescent immunoassay for the determination of CYFRA21-1:analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer[J].Clin Chem,1999,45(11):1944-1953.
[10]	Deng YF,Chen P,Lin YZ,et al.Analytical and clinical evaluation of CYFRA21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma[J].J Laryngol Otol,2003,117(3):190-194.
[11]	Nomura F,Ishijima M,Kuwa K,et al.Serum des-gamma-carboxy prothrombin levels determination by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carci-nom[J].Am J Gastroenterol,1999,94(3):650-654.
[12]	Shimada M,Yamashita Y,Hamatsu T,et al.The role of des-gamma-carboxy prothrombin levels in hepatocellular carcinom and liver tissues[J].Cancer Lett,2000,159(1):87-94.
[13]	Shimizu A,Shiraki K,Ito T,et al.Sequential fluctuation parrern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cir-rhosis[J].Int J Mol Med,2002,9(3):245-250.
[14]	Geiger DU,Wu AHB,Apple FS,et al.Multicenter evaluation of an automated assay for troponin I[J].Clin Chem,2002,48(6Pt1):869-876.

[1]	韩佩珍 . 化学发光免疫分析. 国际放射医学核医学杂志, 2000, 24(5): 196-201.
[2]	王蔚 , 杨永青 , 卢倜章 . 血清肿瘤标志物判断治疗效果的临床意义. 国际放射医学核医学杂志, 1995, 19(1): 15-18.
[3]	陈鹏 , 宋长祥 , 陆武 , 刘永 , 袁小帅 , 杜鹏 . SPECT同机定位CT引导经皮肺穿刺活检术联合肿瘤标志物检测对周围型肺癌的诊断价值. 国际放射医学核医学杂志, 2018, 42(1): 21-24, 29. doi: 10.3760/cma.j.issn.1673-4114.2018.01.004
[4]	赵保健 . 心肌肌钙蛋白Ⅰ的临床应用及检测方法进展. 国际放射医学核医学杂志, 2003, 27(5): 212-215.
[5]	蒋婷吟 , 查金顺 , 黄春玲 . CLIA、TRUST和TPPA 3种梅毒检测方法的比较. 国际放射医学核医学杂志, 2014, 38(6): 384-386. doi: 10.3760/cma.j.issn.1673-4114.2014.06.009
[6]	丁缙 , 朱华 , 杨志 . 胃癌新型PET分子探针的研发进展. 国际放射医学核医学杂志, 2023, 47(11): 699-706. doi: 10.3760/cma.j.cn121381-202211016-00346
[7]	许杨 . 前列腺特异性抗原及其临床应用. 国际放射医学核医学杂志, 2000, 24(5): 201-205.
[8]	李威 , 王世真 . 恶性肿瘤放射免疫显像中的靶物质:肿瘤标志物. 国际放射医学核医学杂志, 1987, 11(4): 251-252.
[9]	徐欣 , 陆毅 . 肿瘤标志物. 国际放射医学核医学杂志, 1994, 18(6): 278-281.
[10]	赵舒怡 , 储小飞 , 樊赛军 . 血清肿瘤标志物与肿瘤放疗疗效评估的研究进展. 国际放射医学核医学杂志, 2015, 39(5): 427-430. doi: 10.3760/cma.j.issn.1673-4114.2015.05.018
[11]	张海嫦 , 朱家丽 , 万景亚 , 冯学民 , 秦岚 , 沈婕 . 电化学发光免疫法与放射免疫法检测血清皮质醇的对比研究. 国际放射医学核医学杂志, 2017, 41(3): 184-187. doi: 10.3760/cma.j.issn.1673-4114.2017.03.005